Intrinsic value of EXACT Sciences - EXAS

Previous Close

$69.41

  Intrinsic Value

$109.98

stock screener

  Rating & Target

str. buy

+58%

Previous close

$69.41

 
Intrinsic value

$109.98

 
Up/down potential

+58%

 
Rating

str. buy

We calculate the intrinsic value of EXAS stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 6.8

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  426
  658
  983
  1,427
  2,013
  2,767
  3,715
  4,877
  6,276
  7,927
  9,844
  12,035
  14,506
  17,260
  20,294
  23,607
  27,193
  31,047
  35,163
  39,533
  44,154
  49,018
  54,124
  59,469
  65,051
  70,872
  76,935
  83,242
  89,800
  96,616
Variable operating expenses, $m
  294
  453
  677
  981
  1,383
  1,901
  2,550
  3,348
  4,307
  5,440
  6,752
  8,255
  9,950
  11,838
  13,920
  16,192
  18,652
  21,295
  24,118
  27,116
  30,285
  33,622
  37,124
  40,790
  44,619
  48,611
  52,769
  57,096
  61,594
  66,269
Fixed operating expenses, $m
  207
  212
  217
  221
  226
  231
  236
  242
  247
  252
  258
  264
  269
  275
  281
  288
  294
  300
  307
  314
  321
  328
  335
  342
  350
  357
  365
  373
  382
  390
Total operating expenses, $m
  501
  665
  894
  1,202
  1,609
  2,132
  2,786
  3,590
  4,554
  5,692
  7,010
  8,519
  10,219
  12,113
  14,201
  16,480
  18,946
  21,595
  24,425
  27,430
  30,606
  33,950
  37,459
  41,132
  44,969
  48,968
  53,134
  57,469
  61,976
  66,659
Operating income, $m
  -76
  -8
  90
  224
  404
  635
  928
  1,288
  1,722
  2,235
  2,834
  3,517
  4,287
  5,146
  6,093
  7,127
  8,248
  9,452
  10,738
  12,104
  13,548
  15,069
  16,666
  18,337
  20,083
  21,904
  23,800
  25,773
  27,825
  29,957
EBITDA, $m
  -53
  27
  141
  297
  505
  774
  1,113
  1,530
  2,033
  2,628
  3,318
  4,109
  5,001
  5,995
  7,092
  8,289
  9,586
  10,979
  12,468
  14,049
  15,720
  17,481
  19,329
  21,263
  23,283
  25,391
  27,585
  29,868
  32,243
  34,711
Interest expense (income), $m
  0
  0
  3
  6
  12
  19
  28
  40
  55
  73
  95
  121
  152
  186
  225
  269
  317
  369
  426
  487
  552
  621
  694
  771
  852
  936
  1,024
  1,116
  1,212
  1,312
  1,416
Earnings before tax, $m
  -76
  -11
  83
  213
  385
  608
  888
  1,233
  1,649
  2,140
  2,713
  3,365
  4,101
  4,921
  5,824
  6,811
  7,878
  9,026
  10,251
  11,552
  12,927
  14,375
  15,895
  17,485
  19,147
  20,879
  22,684
  24,561
  26,513
  28,542
Tax expense, $m
  0
  0
  22
  57
  104
  164
  240
  333
  445
  578
  732
  909
  1,107
  1,329
  1,573
  1,839
  2,127
  2,437
  2,768
  3,119
  3,490
  3,881
  4,292
  4,721
  5,170
  5,637
  6,125
  6,631
  7,158
  7,706
Net income, $m
  -76
  -11
  61
  155
  281
  444
  648
  900
  1,204
  1,562
  1,980
  2,456
  2,994
  3,592
  4,252
  4,972
  5,751
  6,589
  7,483
  8,433
  9,437
  10,494
  11,603
  12,764
  13,977
  15,242
  16,559
  17,929
  19,354
  20,835

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  387
  598
  894
  1,297
  1,830
  2,516
  3,377
  4,434
  5,706
  7,207
  8,949
  10,941
  13,188
  15,691
  18,449
  21,461
  24,721
  28,225
  31,966
  35,939
  40,140
  44,562
  49,204
  54,063
  59,138
  64,429
  69,941
  75,674
  81,636
  87,833
Adjusted assets (=assets-cash), $m
  387
  598
  894
  1,297
  1,830
  2,516
  3,377
  4,434
  5,706
  7,207
  8,949
  10,941
  13,188
  15,691
  18,449
  21,461
  24,721
  28,225
  31,966
  35,939
  40,140
  44,562
  49,204
  54,063
  59,138
  64,429
  69,941
  75,674
  81,636
  87,833
Revenue / Adjusted assets
  1.101
  1.100
  1.100
  1.100
  1.100
  1.100
  1.100
  1.100
  1.100
  1.100
  1.100
  1.100
  1.100
  1.100
  1.100
  1.100
  1.100
  1.100
  1.100
  1.100
  1.100
  1.100
  1.100
  1.100
  1.100
  1.100
  1.100
  1.100
  1.100
  1.100
Average production assets, $m
  105
  162
  242
  351
  495
  681
  914
  1,200
  1,544
  1,950
  2,422
  2,961
  3,569
  4,246
  4,992
  5,807
  6,690
  7,638
  8,650
  9,725
  10,862
  12,059
  13,315
  14,629
  16,003
  17,435
  18,926
  20,477
  22,091
  23,768
Working capital, $m
  -9
  -13
  -20
  -29
  -40
  -55
  -74
  -98
  -126
  -159
  -197
  -241
  -290
  -345
  -406
  -472
  -544
  -621
  -703
  -791
  -883
  -980
  -1,082
  -1,189
  -1,301
  -1,417
  -1,539
  -1,665
  -1,796
  -1,932
Total debt, $m
  51
  119
  214
  344
  516
  737
  1,014
  1,354
  1,764
  2,247
  2,808
  3,449
  4,173
  4,979
  5,867
  6,837
  7,887
  9,015
  10,220
  11,499
  12,851
  14,276
  15,770
  17,335
  18,969
  20,673
  22,447
  24,294
  26,213
  28,209
Total liabilities, $m
  125
  192
  288
  418
  589
  810
  1,087
  1,428
  1,837
  2,321
  2,882
  3,523
  4,246
  5,052
  5,941
  6,910
  7,960
  9,088
  10,293
  11,573
  12,925
  14,349
  15,844
  17,408
  19,042
  20,746
  22,521
  24,367
  26,287
  28,282
Total equity, $m
  262
  405
  606
  879
  1,241
  1,706
  2,290
  3,006
  3,868
  4,886
  6,067
  7,418
  8,941
  10,638
  12,509
  14,551
  16,761
  19,137
  21,673
  24,367
  27,215
  30,213
  33,360
  36,654
  40,095
  43,683
  47,420
  51,307
  55,349
  59,551
Total liabilities and equity, $m
  387
  597
  894
  1,297
  1,830
  2,516
  3,377
  4,434
  5,705
  7,207
  8,949
  10,941
  13,187
  15,690
  18,450
  21,461
  24,721
  28,225
  31,966
  35,940
  40,140
  44,562
  49,204
  54,062
  59,137
  64,429
  69,941
  75,674
  81,636
  87,833
Debt-to-equity ratio
  0.190
  0.290
  0.350
  0.390
  0.420
  0.430
  0.440
  0.450
  0.460
  0.460
  0.460
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
Adjusted equity ratio
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678
  0.678

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -76
  -11
  61
  155
  281
  444
  648
  900
  1,204
  1,562
  1,980
  2,456
  2,994
  3,592
  4,252
  4,972
  5,751
  6,589
  7,483
  8,433
  9,437
  10,494
  11,603
  12,764
  13,977
  15,242
  16,559
  17,929
  19,354
  20,835
Depreciation, amort., depletion, $m
  23
  35
  51
  73
  101
  139
  185
  242
  311
  392
  484
  592
  714
  849
  998
  1,161
  1,338
  1,528
  1,730
  1,945
  2,172
  2,412
  2,663
  2,926
  3,201
  3,487
  3,785
  4,095
  4,418
  4,754
Funds from operations, $m
  -53
  24
  112
  228
  382
  582
  834
  1,143
  1,515
  1,955
  2,465
  3,049
  3,707
  4,441
  5,250
  6,133
  7,089
  8,116
  9,213
  10,378
  11,609
  12,906
  14,266
  15,690
  17,178
  18,729
  20,344
  22,025
  23,772
  25,589
Change in working capital, $m
  -3
  -5
  -7
  -9
  -12
  -15
  -19
  -23
  -28
  -33
  -38
  -44
  -49
  -55
  -61
  -66
  -72
  -77
  -82
  -87
  -92
  -97
  -102
  -107
  -112
  -116
  -121
  -126
  -131
  -136
Cash from operations, $m
  -50
  29
  118
  237
  394
  597
  852
  1,166
  1,543
  1,988
  2,503
  3,092
  3,757
  4,496
  5,311
  6,199
  7,161
  8,193
  9,295
  10,465
  11,702
  13,003
  14,368
  15,797
  17,289
  18,845
  20,465
  22,151
  23,904
  25,725
Maintenance CAPEX, $m
  -13
  -21
  -32
  -48
  -70
  -99
  -136
  -183
  -240
  -309
  -390
  -484
  -592
  -714
  -849
  -998
  -1,161
  -1,338
  -1,528
  -1,730
  -1,945
  -2,172
  -2,412
  -2,663
  -2,926
  -3,201
  -3,487
  -3,785
  -4,095
  -4,418
New CAPEX, $m
  -39
  -57
  -80
  -109
  -144
  -186
  -233
  -286
  -344
  -406
  -471
  -539
  -608
  -677
  -747
  -815
  -882
  -948
  -1,012
  -1,075
  -1,137
  -1,197
  -1,256
  -1,315
  -1,373
  -1,432
  -1,491
  -1,552
  -1,613
  -1,677
Cash from investing activities, $m
  -52
  -78
  -112
  -157
  -214
  -285
  -369
  -469
  -584
  -715
  -861
  -1,023
  -1,200
  -1,391
  -1,596
  -1,813
  -2,043
  -2,286
  -2,540
  -2,805
  -3,082
  -3,369
  -3,668
  -3,978
  -4,299
  -4,633
  -4,978
  -5,337
  -5,708
  -6,095
Free cash flow, $m
  -102
  -49
  6
  79
  180
  313
  483
  697
  959
  1,273
  1,641
  2,069
  2,557
  3,105
  3,715
  4,386
  5,117
  5,907
  6,756
  7,660
  8,620
  9,634
  10,700
  11,819
  12,990
  14,213
  15,487
  16,814
  18,195
  19,630
Issuance/(repayment) of debt, $m
  47
  68
  95
  130
  172
  221
  277
  340
  409
  483
  561
  641
  723
  806
  888
  970
  1,050
  1,128
  1,205
  1,279
  1,352
  1,424
  1,495
  1,565
  1,634
  1,704
  1,775
  1,846
  1,920
  1,995
Issuance/(repurchase) of shares, $m
  175
  154
  140
  118
  80
  21
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  222
  222
  235
  248
  252
  242
  277
  340
  409
  483
  561
  641
  723
  806
  888
  970
  1,050
  1,128
  1,205
  1,279
  1,352
  1,424
  1,495
  1,565
  1,634
  1,704
  1,775
  1,846
  1,920
  1,995
Total cash flow (excl. dividends), $m
  119
  172
  241
  327
  432
  555
  761
  1,038
  1,368
  1,756
  2,202
  2,710
  3,280
  3,911
  4,603
  5,356
  6,167
  7,036
  7,960
  8,940
  9,972
  11,058
  12,195
  13,384
  14,624
  15,917
  17,262
  18,661
  20,115
  21,626
Retained Cash Flow (-), $m
  -175
  -154
  -201
  -273
  -361
  -465
  -584
  -717
  -862
  -1,018
  -1,181
  -1,351
  -1,523
  -1,697
  -1,870
  -2,042
  -2,210
  -2,375
  -2,537
  -2,694
  -2,848
  -2,999
  -3,147
  -3,294
  -3,441
  -3,588
  -3,736
  -3,888
  -4,042
  -4,201
Prev. year cash balance distribution, $m
  357
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  301
  19
  40
  54
  70
  90
  177
  321
  506
  738
  1,021
  1,360
  1,757
  2,214
  2,733
  3,314
  3,957
  4,660
  5,424
  6,246
  7,125
  8,059
  9,048
  10,090
  11,184
  12,329
  13,525
  14,773
  16,072
  17,424
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  289
  17
  35
  44
  55
  65
  119
  200
  291
  387
  485
  580
  668
  743
  802
  842
  861
  858
  835
  794
  737
  669
  593
  514
  435
  360
  290
  229
  175
  131
Current shareholders' claim on cash, %
  90.4
  85.4
  82.5
  80.9
  80.2
  80.1
  80.1
  80.1
  80.1
  80.1
  80.1
  80.1
  80.1
  80.1
  80.1
  80.1
  80.1
  80.1
  80.1
  80.1
  80.1
  80.1
  80.1
  80.1
  80.1
  80.1
  80.1
  80.1
  80.1
  80.1

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.

FINANCIAL RATIOS  of  EXACT Sciences (EXAS)

Valuation Ratios
P/E Ratio -45.8
Price to Sales 77.3
Price to Book 22.8
Price to Tangible Book
Price to Cash Flow -58.9
Price to Free Cash Flow -52.8
Growth Rates
Sales Growth Rate 153.8%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -31.8%
Cap. Spend. - 3 Yr. Gr. Rate 10.8%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 1.5%
Total Debt to Equity 1.5%
Interest Coverage 0
Management Effectiveness
Return On Assets -45.1%
Ret/ On Assets - 3 Yr. Avg. -45.1%
Return On Total Capital -49.6%
Ret/ On T. Cap. - 3 Yr. Avg. -48.9%
Return On Equity -50.5%
Return On Equity - 3 Yr. Avg. -49.6%
Asset Turnover 0.3
Profitability Ratios
Gross Margin 54.5%
Gross Margin - 3 Yr. Avg. -19%
EBITDA Margin -157.6%
EBITDA Margin - 3 Yr. Avg. -1780.7%
Operating Margin -170.7%
Oper. Margin - 3 Yr. Avg. -1860.3%
Pre-Tax Margin -168.7%
Pre-Tax Margin - 3 Yr. Avg. -1857.9%
Net Profit Margin -168.7%
Net Profit Margin - 3 Yr. Avg. -1857.9%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

EXAS stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the EXAS stock intrinsic value calculation we used $265.989 million for the last fiscal year's total revenue generated by EXACT Sciences. The default revenue input number comes from 0001 income statement of EXACT Sciences. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our EXAS stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for EXAS is calculated based on our internal credit rating of EXACT Sciences, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of EXACT Sciences.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of EXAS stock the variable cost ratio is equal to 69.5%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $203 million in the base year in the intrinsic value calculation for EXAS stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for EXACT Sciences.

Corporate tax rate of 27% is the nominal tax rate for EXACT Sciences. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the EXAS stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for EXAS are equal to 24.6%.

Life of production assets of 4.6 years is the average useful life of capital assets used in EXACT Sciences operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for EXAS is equal to -2%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $520.418 million for EXACT Sciences - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 97.792 million for EXACT Sciences is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of EXACT Sciences at the current share price and the inputted number of shares is $6.8 billion.

RELATED COMPANIES Price Int.Val. Rating
DGX Quest Diagnost 95.04 117.37  hold
CGIX Cancer Genetic 0.600 0.04  str.sell
NVTA Invitae 12.24 0.14  str.sell
NEO NeoGenomics 16.50 2.34  str.sell
ENZ Enzo Biochem 3.21 11.55  str.buy
TROV TrovaGene 0.780 0.09  str.sell

COMPANY NEWS

▶ Is Exact Sciences Corporation a Buy?   [Nov-06-18 06:32AM  Motley Fool]
▶ Exact Sciences Stock: Buy at What Level?   [01:23PM  TheStreet.com]
▶ Why Accuray Is Soaring Today   [Oct-31-18 02:18PM  Motley Fool]
▶ Exact Sciences: 3Q Earnings Snapshot   [05:03PM  Associated Press]
▶ 7 Rising Healthcare Stocks to Consider   [Oct-29-18 12:09PM  InvestorPlace]
▶ 7 Cheap Biotech Stocks to Buy Now   [11:39AM  InvestorPlace]
▶ Exact Sciences CEO talks new partnership with Pfizer   [Aug-22-18 06:54PM  CNBC Videos]
▶ [$$] Exact Sciences Shares Jump 26%   [02:43PM  The Wall Street Journal]
▶ Four stocks to watch in today's blitz   [01:53PM  CNBC Videos]
▶ Exact Sciences begins work on new HQ in Madison's University Research Park   [Aug-15-18 12:36PM  American City Business Journals]
▶ GlycoMimetics Stock Has Substantial Upside   [Aug-10-18 03:17PM  InvestorPlace]
▶ Is Exact Sciences a Buy on the Dip?   [Aug-06-18 09:36AM  Motley Fool]
▶ Exact Sciences: 2Q Earnings Snapshot   [Aug-01-18 05:37PM  Associated Press]
▶ 3 'Strong Buy' Healthcare Stocks Poised to Surge   [Jul-25-18 01:10PM  TheStreet.com]
▶ Why Exact Sciences Shares Are Rallying 13.8% in 2018   [Jul-07-18 07:15AM  Motley Fool]
▶ 3 Small Cap Stocks That Can Thrive Amid a Trade War   [Jun-21-18 06:00AM  Investopedia]
▶ This Biotech Said It Can Detect Liver Cancer In Your Blood And Broke Out   [Jun-06-18 04:10PM  Investor's Business Daily]
▶ Where Will Exact Sciences Corporation Be in 5 Years?   [May-29-18 08:18AM  Motley Fool]
▶ 4 Biotech Stocks Set to Rise By 14% or More   [May-14-18 06:00AM  Investopedia]
▶ Exact Sciences teams with Vince Lombardi foundation in fight against colon cancer   [May-03-18 12:36PM  American City Business Journals]
▶ [$$] Exact Sciences: A Big Opportunity?   [May-02-18 04:08PM  Barrons.com]
▶ Why Exact Sciences Is Soaring Today   [12:30PM  Motley Fool]
▶ Exact Sciences: 1Q Earnings Snapshot   [05:06AM  Associated Press]
▶ Exact Sciences revenue jumps 87% in first quarter, topping consensus   [Apr-26-18 05:11PM  American City Business Journals]
▶ Don't Get Greedy With Exact Sciences Corporation Stock   [Apr-25-18 06:02AM  Motley Fool]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.